

## APPENDIX

**Supplemental Table 1.** Objective SCORAD (%), plasma GLA levels ( $\mu\text{g/ml}$ ), and plasma DGLA levels ( $\mu\text{g/ml}$ ) in the intention-to-treat population ( $n = 21$ ) assessed at baseline, and 4 and 12 weeks after initiation of EPO treatment

Time point	Mean (SD)	Median (lower quartile, upper quartile)
<b>Objective SCORAD (%)</b>		
Baseline	26.7 (7.64)	29.1 (21.1, 32.8)
4 weeks	18.6 (10.25)	18.3 (13.0, 27.1)
12 weeks	12.5 (8.73)	11.2 (4.0, 20.4)
<b>Plasma GLA levels (<math>\mu\text{g/ml}</math>)</b>		
Baseline	9.46 (5.02)	8.78 (5.45, 12.36)
4 weeks	15.52 (8.59)	14.45 (8.58, 19.08)
12 weeks	15.70 (5.02)	16.04 (13.15, 18.21)
<b>Plasma DGLA levels (<math>\mu\text{g/ml}</math>)</b>		
Baseline	38.01 (22.93)	34.73 (18.82, 50.86)
4 weeks	46.89 (27.59)	40.38 (26.66, 55.62)
12 weeks	48.73 (32.33)	38.84 (31.72, 62.59)